Novum

1. Aquestive Therapeutics, Inc. $443,133 8 payments
2. Roche Molecular Systems, Inc. $368,490 7 payments
3. Merck Sharp & Dohme Corporation $75,889 11 payments

1. Rd006866 $368,490 7 payments
2. A Phase 1, Open-Label, Partially Randomized Adaptive Dosing Crossover Study to Compare the Pharmacokinetics and Pharmacodynamics of Epinephrine Following Administration of Two Formulations of Dipivefrin Sublingual Film and Epinephrine Administered As Intra $242,724 2 payments
3. A Randomized, Open-Label, Two-Sequence, Two-Period, Two-Treatment Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of Valtoco Diazepam Nasal Spray in Healthy Adult Subjects $200,409 6 payments
4. A Two-Period Study to Evaluate the Effects of Multiple Oral Doses of Diltiazem on the Single-Dose Pharmacokinetics of MK-8189 in Healthy Subjects. $41,117 5 payments
5. A two-period fixed sequence study to evaluate the effects of pyrimethamine, a potent inhibitor of MATE1,2K, on the pharmacokinetics of MK-7264 in healthy adults $19,352 2 payments
6. A Study to Characterize the Pharmacokinetic Performance of Different Formulations of MK-7264 in Healthy Adult Subjects under Fed and Fasted Conditions. $10,041 3 payments
7. An Open Label Clinical Trial to Evaluate the Pharmacokinetics and Relative Bioavailability of Five Formulations of MK-4250 in Healthy Adult Subjects $5,378 1 payment

1. Other $324,389 4 payments
2. Patient care $40,222 1 payment
3. Non-patient care $40,222 1 payment
4. Medical research writing or publication $38,300 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.